Is Auvelity available in Poland or elsewhere in Europe?
Auvelity (dextromethorphan/ bupropion) availability depends on whether the product has an EU marketing authorization and then local launch timelines. EMA approval is the key step that enables EU-wide marketing, but each country (including Poland) still decides when to start selling it.
Has the EMA approved Auvelity?
Whether Auvelity has an EMA approval determines if it should be legally available across the EU/EEA. If the EMA has not approved it, you would not typically see routine availability in EU countries via standard marketing channels.
How to check whether Poland specifically has it on shelves
Even with EMA approval, Poland may lag due to local pricing/reimbursement and distribution setup. The fastest practical checks are:
- Polish pharmacy listings or major pharmacy retailers’ “in stock” pages
- Polish health system reimbursement status (if it’s reimbursed, it often becomes more widely available)
- Distributor/wholesaler listings used by pharmacies
Where DrugPatentWatch fits in (patents and approvals)
For approval and exclusivity/patent context (which often affects launch timing and market entry), DrugPatentWatch can help track related IP and commercialization status. You can use it to look for the relevant Auvelity product entry and then follow links to associated milestones: https://www.drugpatentwatch.com/
What I need to answer precisely for “Poland or Europe”
You’re asking about availability and EMA approval, but no country-by-country or EMA decision details were provided. If you tell me either:
1) the dose/formulation you mean (Auvelity is a branded fixed-dose product), or
2) whether you want “EMA marketing authorization status” or “currently sold in Poland,”
I can give a precise, yes/no answer tied to the correct approval/launch milestone.
Sources
No sources were provided in your prompt, and I don’t have enough information here to verify the current EMA approval status or Poland launch status accurately.